Group 1 - The company approved a share repurchase plan on January 8, 2025, with a total amount not less than RMB 200 million and not exceeding RMB 400 million [1][2] - The estimated number of shares to be repurchased is approximately 13.51 million to 27.03 million, accounting for 1.57% to 3.14% of the total share capital [1] - The implementation period for the repurchase plan is 12 months from the date of board approval [1] Group 2 - The total repurchase amount was adjusted to not less than RMB 350 million and not exceeding RMB 700 million [2] - The maximum repurchase price was revised from RMB 14.80 per share to RMB 14.47 per share, effective from May 29, 2025 [3] - The estimated number of shares to be repurchased under the new price cap is approximately 24.19 million to 48.38 million, accounting for 2.81% to 5.62% of the total share capital [3] Group 3 - As of June 30, 2025, the company repurchased 47.27 million shares, representing 5.49% of the total share capital, with a total transaction amount of RMB 608.72 million [3][4] - The highest purchase price was RMB 14.41 per share, and the lowest was RMB 11.86 per share [3] Group 4 - The repurchase is funded by the company's own funds and complies with relevant laws and regulations [4] - The company will continue to implement the repurchase plan based on market conditions and fulfill information disclosure obligations [5]

证券分析师：张冬冬 E-MAIL：zhangdd@tpyzq.com 分析师登记编号：S1190522040001 证券分析师：吴步升 E-MAIL：wubs@tpyzq.com 分析师登记编号：S1190524110002 大类资产跟踪 债券市场：利率债涨跌不一，短端几乎持平，长端上涨。股市方面上 证指数放量突破颈线压制，且呈均线排列结构，虽然基本面的疲弱仍将支 撑债市，但股市若继续走强仍将压制债市表现，预计债市后续将高位震荡 运行。后续展望：股市大盘突破，债市预计高位震荡。 2025 年 07 月 01 日 投资策略 策略日报（2025.07.01）：指数分化 相关研究报告 <<策略日报（2025.06.30）：创业板指 领涨>>--2025-07-01 A 股：三大指数分化，沪指领涨，创新药概念爆发。市场全天成交额 1.49 万亿，较前一日缩量 0.02 万亿，个股涨跌分化，2514 只个股上涨， 2394 只个股下跌。沪指技术面上指数突破了 3 月份的高点，上涨空间已 经打开。有三个观察点来判断行情的强弱支撑是否有效：一是前期油价的 高点也是地缘风险消退和指数止稳的起点，因此 6 月 23 日上涨的低 ...

Market Overview - On July 1, the A-share market opened high and experienced slight fluctuations, with the Shanghai Composite Index facing resistance around 3454 points[3] - The Shanghai Composite Index closed at 3457.75 points, up 0.39%, while the Shenzhen Component Index rose 0.11% to 10,476.29 points[9] - Total trading volume for both markets was 1,496.8 billion yuan, slightly lower than the previous trading day[9] Sector Performance - Strong performers included banking, electricity, chemical pharmaceuticals, and fiberglass industries, while software development, internet services, batteries, and auto parts lagged[4] - Over 50% of stocks in the two markets saw gains, with notable increases in fiberglass, chemical pharmaceuticals, and electricity sectors[9] Valuation Metrics - The average price-to-earnings (P/E) ratios for the Shanghai Composite and ChiNext indices are 14.13 times and 38.67 times, respectively, indicating a mid-level valuation over the past three years[4] - The trading volume is above the median level for the past three years, suggesting a healthy market activity[4] Economic Outlook - China's economy continues to show moderate recovery, driven by consumption and investment[4] - Long-term capital inflows are increasing, with steady growth in ETF sizes and continuous inflow from insurance funds, providing significant support to the market[4] Investment Strategy - A balanced strategy is recommended to optimize portfolio structure amid market fluctuations, focusing on growth stocks with strong mid-year performance and reasonable valuations[4] - Short-term investment opportunities are suggested in banking, electricity, chemical pharmaceuticals, and shipbuilding sectors[4] Risk Factors - Potential risks include unexpected overseas economic downturns, domestic policy changes, and macroeconomic disturbances[5]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Core Viewpoint - The company expects a significant increase in net profit for the period from January 1, 2025, to June 30, 2025, projecting a net profit attributable to shareholders of 3.3 billion to 3.75 billion yuan, representing a growth of 50% to 70% compared to the same period last year [1] Financial Performance - The net profit excluding non-recurring gains and losses is projected to be between 3.25 billion and 3.7 billion yuan, which indicates a growth of 51% to 71% year-on-year [1] - The basic earnings per share are estimated to be between 1.07 yuan and 1.22 yuan [1] Business Segment Performance - The nutrition product segment has seen an increase in both sales volume and sales prices compared to the same period last year, contributing to the overall improvement in operating performance [1]

截至2025年7月1日，A股三大指数涨跌不一。其中上证指数收涨0.39%，报3457.75点；深证成指收涨 0.11%，报10476.29点；创业板指收跌0.24%，报2147.92点。两市总成交额1.47万亿元。 行业热度看，玻璃玻纤表现亮眼，当日大涨5.11%；专业连锁、化学制药紧随其后，分别上涨4.04%、 2.96%。 截至今日收盘，全市场共计562只非货ETF上涨，上涨比例达到48%。上证科创板生物医药指数上涨 2.99%，科创医药ETF、科创生物医药ETF、科创医药ETF嘉实、科创医药ETF基金，分别上涨3.18%、 3.06%、3.03%、3.02%；中证沪港深创新药产业指数上涨1.13%，创新药ETF富国、创新药ETF国泰，分 别上涨5.88%、3.90%；深证主板50指数上涨0.21%， | 排名 | 证券代码 | 证券名称 | 涨幅 | 基金管理人 | 投资类型 | | --- | --- | --- | --- | --- | --- | | I | 159748.SZ | 创新药ETF富国 | 5.88% | 富国基金 | 股票型 | | 2 | 159570.SZ | 港股通创新药E ...

Group 1 - The stock of Microchip Biotech (688321) has a comprehensive score of 64.12, indicating a strong performance [1] - The main cost analysis shows that the current main cost is 26.50 yuan, with a 5-day main cost of 24.59 yuan, a 20-day main cost of 23.33 yuan, and a 60-day main cost of 19.33 yuan [1] - Over the past year, the stock has not experienced any limit-up or limit-down events [1] Group 2 - The short-term pressure level is at 25.22 yuan, while the short-term support level is at 23.75 yuan [2] - The stock price has the potential to strengthen in the short term if it breaks through the short-term pressure level, and in the medium term if it surpasses the medium pressure level of 25.22 yuan [2] - On July 1, 2025, the net inflow of main funds was 115.30 million yuan, accounting for 17% of the total transaction amount [2]

Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with key products including various injections and capsules that are unique in the market and covered by national medical insurance [2]. Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.90 million yuan, representing a significant year-on-year decline of 960.04%. The gross profit margin stood at 66.62% [3]. Market Position - As of July 1, ST Jingfeng's stock closed at 6.06 yuan, reflecting an increase of 1.68%. The rolling price-to-earnings (PE) ratio reached 37.67, with a total market capitalization of 5.33 billion yuan. In comparison, the average PE ratio for the chemical pharmaceutical industry is 54.81, and the industry median is 32.58, placing ST Jingfeng at the 96th position within the industry [1][3]. Capital Flow - On July 1, ST Jingfeng experienced a net inflow of 9.70 million yuan in principal funds, although the overall trend over the past five days showed a net outflow of 2.44 million yuan [1].

Market Overview - The market experienced fluctuations with mixed performance among the three major indices, where the Shanghai Composite Index rose by 0.39%, the Shenzhen Component Index increased by 0.11%, while the ChiNext Index fell by 0.24% [1] Sector Performance - Sectors such as glass fiber, chemical pharmaceuticals, and biological products showed significant gains, while multi-financial, software development, and battery sectors faced declines [1] - Major capital inflows were observed in the chemical pharmaceuticals, electric power, and banking sectors [1] Innovation Drug Sector - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research and development [2] - According to Guojin Securities, the innovative drug sector is currently undervalued, with an increase in the number and quality of new drug approvals in China since the beginning of 2025 [2] Gold Market Outlook - U.S. President Trump criticized the Federal Reserve for not lowering interest rates, with expectations of a rate cut later this year and three cuts next year [3] - China Galaxy Securities predicts that COMEX gold prices may steadily break through $3,300 per ounce, with potential to reach $3,500 in extreme risk scenarios [3] Banking Sector Analysis - The People's Bank of China indicated a continuation of accommodative monetary policy, with expectations for further interest rate cuts and a potential reserve requirement ratio reduction [3] - Guosheng Securities highlighted the ongoing attractiveness of the banking sector, citing a dividend yield of 5.13% compared to a 10-year government bond yield of 1.66%, indicating a significant yield spread [4]

（文章来源：每日经济新闻） 减重药物领域持续受到关注，信达生物的GLP-1R/GCGR双重激动剂玛仕度肽获批上市，成为全球首个 双靶点减重药，其Ⅲ期临床数据显示显著减重及代谢改善效果。长效/口服制剂及多靶点分子是GLP-1类 减重药研发主流方向，国内企业在该领域优势显著，已有多起重磅授权交易。当前医药生物板块PE估 值为27.67倍，处于历史中低位水平，相对沪深300估值溢价为124%。 化学制药子板块年初截至目前涨19.41%，表现突出。建议关注创新药械及GLP-1赛道的商业化机会，同 时留意器械设备、中药等细分领域。 创新药ETF国泰跟踪的是SHS创新药（人民币）指数，该指数由中 证指数有限公司编制，从A股市场中选取主营创新药物研发、生产和销售的上市公司证券作为指数样 本，聚焦生物医药行业，反映具备创新能力的医药相关上市公司证券的整体表现。 消息面上，2025年6月25日《学习时报》刊文强调创新药对国家发展的战略意义，提出完善多层次资本 市场支持医药企业、设立政府引导基金等五项措施，以构建可持续创新投融资体系。6月26日江西省发 布生物医药行业商业秘密保护指南，针对创新药物研发、中医药特色技术等核心领域， ...